AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03342898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline (0.9% NaCl) SC injection.
Trial: NCT01717898
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
Trial: NCT00040872
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00040872
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02550262
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml
Trial: NCT00258622
Drug: NS1209
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01146990
Drug: ASQ-3, Bayley III, Neurologic exam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
Trial: NCT04223765
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2/day IV for 3 consecutive days
Trial: NCT02790177
Drug: NORMAL SALINE
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02325986
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
Trial: NCT00640978
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg orally weekly for 4 weeks
Trial: NCT03778047
Drug: HC1119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03493126
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17β-estradiol vaginal cream
Trial: NCT02006706
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 - 25 mg/week
Trial: NCT00604409
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01788046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) three times per week.
Trial: NCT02816853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered.
Trial: NCT01924871
Drug: Desflurane with remifentanil
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
Trial: NCT04110028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04701697
Drug: Recombinant Human Albumin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Recombinant Human Albumin Injection of intravenous infusion
Trial: NCT04701697
Drug: HumanAlbumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive HumanAlbumin of intravenous infusion
Trial: NCT00570765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets were administered orally once daily.
Trial: NCT04234607
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT02254148
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of caffeine given as tablets (day 1 of visits 2 and 3)
Trial: NCT04234607
Drug: TQB2450（blank）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day
Trial: NCT04234607
Drug: Anlotinib（blank)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
Trial: NCT03841773
Drug: Placebo SL Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Trial: NCT04515849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT01508026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo, oral administration
Trial: NCT01722812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical treatment for 14 days
Trial: NCT01919671
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 90 days
Trial: NCT01919671
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 90 days
Trial: NCT00879099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
Trial: NCT01374828
Drug: Ketolorac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
Trial: NCT02176967
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02176967
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00729859
Drug: Acyline + Testosterone gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
Trial: NCT00729859
Drug: Acyline + testosterone gel + anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
Trial: NCT01757327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02052609
Drug: KHK4827 140mg SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental1:KHK4827 140mg subcutaneous injection
Trial: NCT02052609
Drug: KHK4827 210mg SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental2:KHK4827 210mg subcutaneous injection
Trial: NCT02211625
Drug: TRV734 blinded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded, multiple ascending dose
Trial: NCT02211625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV734-matched and oxycodone placebo
Trial: NCT00871325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
Trial: NCT03151343
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill, visually identical to active comparator
Trial: NCT03109730
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
Trial: NCT03109730
Drug: Placebo for ABI-H0731
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the ABI-H0731 tablet
Trial: NCT00850070
Drug: sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
Trial: NCT00850070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
Trial: NCT01724931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01181908
Drug: single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose of GSK1144814 or placebo.
Trial: NCT02835742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04370873
Drug: MK-5475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-5475 32 µg, 100 µg, 195 µg, 360 µg or 380 µg administered as dry powder inhalation according to randomization. Following review of pharmacokinetic (PK) and safety data, a second 7 days of dosing may be initiated. A dose of up to 360 μg up to twice a day may be administered based on PK data. Dosage may be adjusted downwards in Part 2, if indicated by PK results in Part 1.
Trial: NCT04370873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as dry powder inhalation according to randomization
Trial: NCT00579098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once daily for 90 days
Trial: NCT03023462
Drug: Oksykodonhydroklorid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
Trial: NCT01868997
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00506337
Drug: Qingyi granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD.
Trial: NCT04020588
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered for 6 weeks
Trial: NCT04020588
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be administered for 6 weeks
Trial: NCT04020588
Drug: Minocycline 100mg
RxNorm normalized name: minocycline 100 MG
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will be administered for 6 weeks
Trial: NCT02359344
Drug: CNV1014802
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02359344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02215096
Drug: GSK2636771
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
Trial: NCT00704678
Drug: SBR759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g tid
Trial: NCT03784703
Drug: Rosuvastatin 10 Mg Oral Tablet
RxNorm normalized name: rosuvastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
Trial: NCT00076206
Drug: CCI-779
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00076206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01747148
Drug: AVI-7100 versus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose-escalating AVI-7100 versus placebo
Trial: NCT02705872
Drug: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
Trial: NCT02705872
Drug: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
Trial: NCT03935295
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo prepared by Ipsen for use as control
Trial: NCT01997853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
Trial: NCT03540030
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Trial: NCT03540030
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Trial: NCT00569270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
Trial: NCT03715101
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Open-label, one-sequence, multiple administration
Trial: NCT02058173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02985437
Drug: Surfactants
RxNorm normalized name: surfactants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04286399
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Trial: NCT04032652
Drug: Rectal dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
Trial: NCT02388178
Drug: Control toothpaste containing no anti-cavity ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Trial: NCT03913468
Drug: Intravenous Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
Trial: NCT02388178
Drug: Fluoride toothpaste containing fluoride as the anti-cavity ingredient
RxNorm normalized name: sodium fluoride Mouthwash [Oral B Anti-Cavity]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Trial: NCT01088750
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01088750
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00018551
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02219321
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
Trial: NCT02655133
Drug: Physiologic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
Trial: NCT04534582
Drug: EU-Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: healthy volunteers receive EU-Prolia® (60mg) once
Trial: NCT04534582
Drug: US-Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: healthy volunteers receive US-Prolia® (60mg) once
Trial: NCT04534582
Drug: CN-Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: healthy volunteers receive CN-Prolia® (60mg) once
Trial: NCT02389309
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04551885
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT01536743
Drug: PD0332991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle).
Trial: NCT01259765
Drug: VHH batch 203027
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
Trial: NCT01259765
Drug: Placebo product
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
Trial: NCT01313858
Drug: Simponi®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01313858
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given concomitantly with Simponi®
Trial: NCT01126801
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral estradiol 1.0 mg/day for four weeks.
Trial: NCT00313300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0, twice daily, 26 weeks
Trial: NCT02436304
Drug: EXE844 Sterile Otic Suspension, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254941
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metastatic colon cancer, first line treatment with conventional chemotherapy
Trial: NCT01349088
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive capecitabine at 2000 mg/m2.
Trial: NCT00006381
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00249821
Drug: Saizen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saizen® \[somatropin (recombinant deoxyribonucleic acid \[rDNA\] origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Trial: NCT03836599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
Trial: NCT02202187
Drug: GSK2140944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Study Drug
Trial: NCT03764007
Drug: 18F-Fluorocholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously